

Supplementary Materials

Table S4. Number of participants with other von Hippel-Lindau (vHL) phenotypic manifestations.

Manifestation	N vHL patients ^a	N manifestations ^b	References
Central nervous system hemangioblastoma	1600	1009	(12-14, 16, 18, 20, 22, 23, 25-27, 29, 31, 32, 34, 37-40, 44, 45, 48-55)
Retinal angioma	2146	1104	(6, 12-14, 17, 18, 20-29, 31, 32, 34, 36, 38, 40-42, 45, 47, 49-55)
Renal cell carcinoma	3213	1063	(6, 12-32, 34, 36, 38-42, 44, 45, 47, 49-55)
Pancreatic cyst or cystadenoma	1690	649	(6, 15, 17, 18, 23-27, 29, 30, 32, 35, 38, 39, 42, 44, 47, 49, 51-55)
Pancreatic neuroendocrine tumor	1779	226	(6, 14, 15, 17, 19, 21, 23, 24, 29, 35, 38, 42, 49, 51, 52)
Endolymphatic sac tumor	554	19	(6, 24, 26, 27, 30, 47, 51, 53, 55)

^atotal number of vHL participants; ^btotal number of vHL participants with the manifestation;